OTLK
Outlook Therapeutics Embarks on a Defining New Chapter with FDA-Approved LYTENAVA
Outlook Therapeutics, a leading player in the ophthalmic formulation space, has entered a defining new chapter with the recent FDA approval of its LYTENAVA for the treatment of wet AMD. This significant achievement marks a transformational moment for the company and expands its commercial opportunity in the U.S. retina